Compare Aehr Test Systems (AEHR) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs Ascendis Pharma A/S — how do they compare? Aehr Test Systems trades at $131.18 (market cap $3.82B), while Ascendis Pharma A/S trades at $256.37 (market cap $16.67B). The key difference: Ascendis Pharma A/S is far larger — about 4.4× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| AEHR | ASND | |
|---|---|---|
Market Cap | $3.82B | $16.67B |
Sector | Technology | Health |
52-Week High | $117.18 | $277.18 |
52-Week Low | $17.38 | $189.74 |
Enterprise Value | $3.72B | $17.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR Test Systems stock trades at $129.70, up 22.13% in the past 24 hours, with a bullish technical signal from moving averages and strong momentum. Recent earnings beats and a $22 million AI processor order (Accesswire, August 12, 2026) highlight growth potential, though negative net income margins and high P/S of 71.87 reflect valuation concerns amid rapid revenue expansion.
Outlook is mixed: strong AI-driven demand and record bookings support upside, but profitability challenges, insider selling, and customer concentration pose risks. Analyst consensus is cautious with 33% buy ratings, indicating tempered optimism despite technical strength.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
